[et_pb_section fb_built=”1″ _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.5″ _module_preset=”default” background_image=”https:\/\/idafoundation.org\/wp-content\/uploads\/2026\/01\/Oncology_intro_1.jpg” width=”100%” max_width=”none” height=”30vh” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
<\/blockquote>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n[\/et_pb_text][et_pb_text quote_border_color=”#001a71″ _builder_version=”4.27.5″ _module_preset=”default” quote_font_size=”16px” global_colors_info=”{}”]<\/p>\n
Cancer has reached epidemic proportions worldwide. More than 60% of the world\u2019s total new annual cases occur in Africa, Asia, and Central and South America, accounting for 70% of the world\u2019s cancer deaths. Cancer treatment in these regions is often too expensive and not accessible for many. To address this problem, IDA Foundation has developed a basic range of quality oncology products in line with the\u00a0<\/span>WHO Essential Medicines List.<\/a><\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
Partnering for greater access to essential cancer treatment in LMICs<\/h3>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Pfizer<\/h4>\n
In early 2021, IDA Foundation and\u00a0<\/span>Pfizer<\/a>\u00a0<\/span>announced a partnership to provide equitable access to quality cancer treatments in almost seventy low- and middle-income countries (LMICs) across Latin America, Asia, Africa and the Western Pacific region. This supply agreement means that millions more patients will now have the potential to access innovative chemotherapy medicines for multiple types of cancer. Our partnership means that \u00a0an additional 62 countries, not previously served by existing market access agreements, will gain access to sterile injectable treatments. These 62 countries include eleven low- and middle-income markets in the WHO Western Pacific area, which has the highest cancer mortality rate in the world. Read more about this partnership in our\u00a0<\/span>blog<\/a>.<\/p>\n
ATOM coalition<\/h4>\n
Recognising the gap in access to essential cancer treatments, diagnostics and medical technologies, IDA Foundation joined the UICC-led\u00a0<\/span>ATOM Coalition<\/a>\u00a0<\/span>in 2024\u2014a global initiative dedicated to addressing the barriers related to availability, affordability, and appropriate use of oncology medicines in low- and lower-middle income countries (LLMICs).
As part of this commitment, IDA Foundation contributes its expertise in sourcing, quality, and supply chain to strengthen the ATOM Coalition\u2019s\u00a0<\/span>Medicines Access Pathways Model<\/a>.<\/p>\n